{"id":"tar-210","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anorexia"},{"rate":"5-10%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL2108232","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1 and LAG-3, TAR-210 aims to restore and enhance the body's immune response against cancer cells. This is achieved by blocking the inhibitory signals sent by PD-1 and LAG-3, allowing the immune system to attack and destroy cancer cells more effectively.","oneSentence":"TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:27.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05316155","phase":"PHASE1, PHASE2","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-04-11","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":235},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":641},{"nctId":"NCT05567185","phase":"PHASE1","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2023-03-03","conditions":"Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor","enrollment":5},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-42756493"],"phase":"phase_3","status":"active","brandName":"TAR-210","genericName":"TAR-210","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins. Used for Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}